This is a de facto reverse merger where Passage Bio's public listing is acquired by Remix Therapeutics. Pre-merger PASG shareholders face massive dilution (~93% ownership loss) but receive CVRs tied to legacy assets. The combined entity's value depends entirely on REM-422 clinical data. Monitor the S-4 effectiveness, stockholder vote, and any competing bids for Remix given the $17.5M termination fee.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $4.33entry
- T+1 · 5mo ago +8.54%α +9.27% · $4.70
- T+5 · 5mo ago +5.77%α +4.21% · $4.58
- T+20 · 4mo ago +13.16%α +12.64% · $4.90
- T+60 · 8w ago +9.70%α +5.97% · $4.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Passage Bio filed a definitive all-stock merger agreement to acquire Remix Therapeutics, where pre-merger Passage shareholders will own approximately 7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders receive contingent value rights tied to legacy gene therapy milestones.
Key Financial Metrics
Key Facts
- Passage Bio to merge with Remix Therapeutics via all-stock transaction; pre-merger Passage shareholders will own ~7% of combined company, Remix shareholders ~93%
- Remix equity value set at $226M, Passage equity value at $20M in the merger agreement
- Concurrent PIPE financing of at least $99,929,000 (Concurrent Investment Amount) led by Decheng Capital, with $69,999,999.28 from Subscription Agreement alone
- Combined company will be renamed Remix Therapeutics, Inc. and focus on advancing REM-422, an oral MYB mRNA degrader showing 43% ORR in adenoid cystic carcinoma
- Passage shareholders receive one CVR per share for potential payments from Gemma sublicenses (GM1 through July 2028, MLD through Dec 2027)
- Passage to wind down legacy gene therapy programs (PBFT02) and dispose of Legacy Assets prior to closing
- Passage Board recommends approval; Remix stockholders to provide written consent; Passage stockholder meeting required
- Outside date for closing is December 24, 2026, extendable by 90 days if SEC delays S-4 effectiveness
Financial Impact
Pre-merger Passage shareholders diluted to ~7% ownership; Remix valued at $226M vs Passage at $20M; $100M+ PIPE at ~$70M from Subscription Agreement; termination fee of $17.5M payable by Remix to Passage if Remix terminates for superior offer
Risk Factors
- Massive dilution for pre-merger Passage shareholders (~93% ownership loss)
- CVRs tied to Gemma sublicenses may pay zero if milestones not met
- REM-422 is still in clinical development with no approved products
- Passage stockholder vote required; risk of shareholder opposition
- Regulatory and antitrust approvals needed for merger
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001104659-26-077312 |
| Document: tm2618476d2_ex10-6.htm | 0001104659-26-077312 |
| Document: tm2618476d2_ex10-4.htm | 0001104659-26-077312 |
Track record
15 reports on PASG
2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
- Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
- Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
- Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
- Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
- Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
- Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Viewing Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers